2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

In 2018, the International Council for Standardization in Haematology (ICSH) published a consensus document providing guidance for laboratories on measuring direct oral anticoagulants (DOACs). Since that publication, several significant changes related to DOACs have occurred, including the approval of a new DOAC by the Food and Drug Administration, betrixaban, and a specific DOAC reversal agent intended for use when the reversal of anticoagulation with apixaban or rivaroxaban is needed due to life-threatening or uncontrolled bleeding, andexanet alfa. In addition, this ICSH Working Party recognized areas where additional information was warranted, including patient population considerations and updates in point-of-care testing. The information in this manuscript supplements our previous ICSH DOAC laboratory guidance document. The recommendations provided are based on (1) information from peer-reviewed publications about laboratory measurement of DOACs, (2) contributing author's personal experience/expert opinion and (3) good laboratory practice.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Thromb Haemost

Title: Thrombosis and haemostasis

Publisher: Georg Thieme Verlag KG

ISSN (Electronic): 2567-689X

ISSN (Print): 0340-6245

Publication date (Electronic): Aug 2021

Volume: 121

Issue: 8

Affiliations

[1 ] Department of Pharmacy-Namur Thrombosis and Hemostasis Center, University of Namur, Namur, Belgium.

[2 ] Qualiblood SA, Namur, Belgium.

[3 ] Laboratory Corporation of America, Burlington North Carolina, United States.

[4 ] Department of Medicine, McMaster University Medical Centre, Hamilton, Ontario, Canada.

[5 ] Department of Haematology, Sydney Centres for Haemostasis and Thrombosis, Institute of Clinical Pathology and Medical Research, NSW Health Pathology, Westmead Hospital, Westmead, New South Wales, Australia.

[6 ] Department of Hematology-Hemostasis, IRSET-INSERM-1085, University Hospital, Rennes, France.

[7 ] Hospital de Clínicas "Dr Manuel Quintela," Facultad de Medicina, Universidad de la República, Montevideo, Uruguay.

[8 ] Sanno Hospital, Laboratory Medicine, Tokyo, Japan.

[9 ] Cardiology Angiology Center Bethanien, CCB Vascular Center, CCB Coagulation Center, Frankfurt, Germany.

[10 ] Royal Hallamshire Hospital, Coagulation Sheffield, South Yorks, United Kingdom.

[11 ] Hemophilia Treatment Center, University of California, Davis Health System, Sacramento, California, United States.

Article

DOI: 10.1055/a-1450-8178

PubMed ID: 33742436

SO-VID: b0092037-f4b7-468a-9619-16a29f5263a6

History

Data availability:

Comments

Comment on this article

scite_

Cited by 43

See all cited by